AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £500.27m
- £516.94m
- £55.04m
UK's Allergy Therapeutics H1 revenue rises 7%, operating loss widens
Brief: Allergy Therapeutics H1 Pretax Profit GBP -19.33 Million
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2025
Allergy Therapeutics - PDMR Dealings & Shareholding Update
RCS - Allergy Therapeutics - Allergy Therapeutics presents progress at AAAAI
Allergy Therapeutics - Update on funding and total voting rights
Allergy Therapeutics - Chief Strategy Officer and Board appointments
Allergy Therapeutics - Grant of Options under Long Term Incentive Scheme
Brief: Allergy Therapeutics Remains Confident In Delivering Revenue Growth In Year To 30 June 2026
UK's Allergy Therapeutics expected H1 revenue up 7% yr/yr
Allergy Therapeutics - Half Year Trading Update
Allergy Therapeutics - Notice of 2025 Annual General Meeting
Brief: Allergy Therapeutics Says Protect Trial Meets Primary Safety Endpoint At Highest Dose
Brief: Allergy Therapeutics Targeting HKEX Listing Effective First Half Of 2026
Brief: Allergy Therapeutics Screening For Grass MATA MPL to Complete By Early Q1 2026
Allergy Therapeutics - Warrant Exercise and Paydown of Debt
RCS - Allergy Therapeutics - Grass MATA MPL Publications in Allergy Journal
Allergy Therapeutics - Trading update for the year ended 30 June 2025
Allergy Therapeutics - PDMR Dealings